Glycine forte 250 mg

General characteristics. Structure:

Active agent glycine - 250 mg;
excipients: aspartame - 0,4 mg, croscarmellose sodium - 0,1 mg, коповидон - 9,6, magnesium stearate - 2 mg, sorbitol - 7,9 mg.

Description: tablets of white or almost white color, round, a biconvex form from crosswise risky. The insignificant mramornost is allowed.

Pharmacological properties:

Replaceable amino acid, central neurotransmitter of brake type of action. Improves metabolic processes in brain tissues, has antidepressive and sedative effect. Glycine - and GAMK-ergichesky, alfa1-adrenoceptor blocking, antioxidant and anti-toxic action possesses; regulates activity of glutamate (NMDA) receptors at the expense of what reduces the psychoemotional tension, aggression and a conflictness; improves social adaptation and mood; facilitates backfilling and normalizes a dream; increases intellectual working capacity; reduces expressiveness of vegetovascular disturbances (including in a climacteric) and all-brain frustration at an ischemic stroke and a craniocereberal injury, toxic effect of ethanol by the central nervous system.

Pharmacokinetics. Easily gets into the majority of biological liquids and body tissues, including into a brain, does not kumulirut. Quickly collapses in a liver glitsinoksidazy to water and carbon dioxide.

Indications to use:

Stressful states (including psychoemotional tension), the decrease in intellectual working capacity, deviant forms of behavior of children and teenagers, various functional and organic diseases of a nervous system which are followed by hypererethism, emotional instability, decrease in intellectual working capacity and a sleep disorder: neurosises, neurosis-like conditions, effects of neuroinfections and craniocereberal injury, perinatal and other forms of encephalopathies (including alcoholic genesis).
Ischemic stroke.
In narcology - as the medicines (M), increasing intellectual working capacity and reducing psychoemotional tension during remission at the encephalopathy phenomena, organic lesions of the central and peripheral nervous system.

Route of administration and doses:

Sublingual or transbukkalno on 250 mg (in tablets or in the form of powder after crushing of a tablet).
To children, teenagers and adults at a psychoemotional tension, decrease in memory, attention, intellectual working capacity, a delay of intellectual development, at deviant forms of behavior glycine is appointed on ½ tablets 2-3 times a day within 14-30 days.
At the functional and organic lesions of a nervous system which are followed by hypererethism, emotional lability and a sleep disorder, to children up to 3 years appoint ¼ tablets 2-3 times a day within 7-14 days, further on ¼ tablets for 7-10 days once a day. A daily dose - 100-150 mg, course - 2-2.6 g.
To children 3 years are more senior and the adult appoint ½ tablets 2-3 times a day, a course of treatment - 7-14 days, it can be increased up to 30 days, if necessary repeat a course in 30 days.
At sleep disorders appoint in 20 min. prior to a dream or just before a dream on ¼-½ tablets (depending on age).
At an ischemic brain stroke: within the first 3-6 hour from development of a stroke appoint 1 g (4 tablets) transbukkalno or sublingual with 1 teaspoon of water, further during 1-5 days on 1 g/days (4 tablets), then during the subsequent 30 days on ½-to 1 tablet 3 times a day.
In narcology - on ½ tablets 2-3 times a day within 14-30 days. If necessary courses repeat 4-6 times a year.

Features of use:

At patients with bent to arterial hypotension appointment is made in smaller doses and at control of arterial pressure, at its decrease below usual level reception stops.

Side effects:

Allergic reactions.

Interaction with other medicines:

Weakens expressiveness of side effects of antipsychotic HP (neuroleptics), anxiolytics, antidepressants, somnolent and anticonvulsant HP.

Contraindications:

Hypersensitivity.

With care:
Arterial hypotension.

Storage conditions:

Period of validity: 2 years. Not to apply after a period of validity. In the dry, protected from light place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets zashchechny 250 mg. On 10 or 30 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished.
On 1, 2, 3, 5, 6, 9, 10 blister strip packagings on 10 tablets or on 1, 2, 3 blister strip packagings on 30 tablets together with the application instruction place in a pack from a cardboard.